Published in J Clin Pharmacol on June 01, 2003
The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest (2007) 2.48
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues. J Med Chem (2008) 1.34
Iron homeostasis and toxicity in retinal degeneration. Prog Retin Eye Res (2007) 1.28
An update on iron chelation therapy. Blood Transfus (2012) 1.19
Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res (2006) 1.16
Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology (2007) 1.11
A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica (2010) 1.01
Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury. Free Radic Biol Med (2014) 0.98
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity. J Med Chem (2006) 0.93
Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther Clin Risk Manag (2007) 0.91
Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. J Blood Med (2011) 0.90
Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J (2014) 0.88
Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.87
Impact of the 3,6,9-trioxadecyloxy group on desazadesferrithiocin analogue iron clearance and organ distribution. J Med Chem (2007) 0.86
Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy. Exp Hematol (2007) 0.85
Iron: a target for the management of Kaposi's sarcoma? BMC Cancer (2004) 0.85
Recent advances in β-thalassemias. Pediatr Rep (2011) 0.82
The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues. J Med Chem (2010) 0.82
Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine. Haematologica (2012) 0.81
Deferasirox: appraisal of safety and efficacy in long-term therapy. J Blood Med (2013) 0.80
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World J Methodol (2014) 0.80
Update on the use of deferasirox in the management of iron overload. Ther Clin Risk Manag (2009) 0.80
Desferrithiocin analogues and nephrotoxicity. J Med Chem (2008) 0.77
Polymeric nanocarriers for the treatment of systemic iron overload. Mol Cell Ther (2015) 0.76
Management of the thalassemias. Cold Spring Harb Perspect Med (2013) 0.76
Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles. J Med Chem (2012) 0.75
Effects of renal impairment on the pharmacokinetics of orally administered deferiprone. Br J Clin Pharmacol (2016) 0.75
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood (2005) 6.07
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica (2004) 5.21
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet (2003) 3.07
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood (2005) 2.75
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica (2006) 2.54
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood (2005) 2.45
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology (2004) 2.41
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica (2006) 2.14
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica (2008) 2.12
Purging iron from the heart. Br J Haematol (2004) 2.07
Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica (2003) 1.94
Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int (2004) 1.78
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood (2002) 1.77
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol (2007) 1.77
Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet (2007) 1.57
Feasibility and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) in children. J Pediatr Gastroenterol Nutr (2012) 1.55
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica (2008) 1.54
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood (2014) 1.54
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood (2012) 1.49
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood (2003) 1.46
Pregnancy and beta-thalassemia: an Italian multicenter experience. Haematologica (2009) 1.42
Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. Br J Haematol (2014) 1.40
Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica (2010) 1.31
A valine deletion of ferroportin 1: a common mutation in hemochromastosis type 4. Blood (2002) 1.31
Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling. Am J Pathol (2007) 1.26
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol (2009) 1.23
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood (2011) 1.23
Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol (2004) 1.22
Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord (2011) 1.21
Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem (2003) 1.21
The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol (2002) 1.21
Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res (2003) 1.19
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica (2008) 1.18
Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood (2005) 1.17
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann N Y Acad Sci (2005) 1.14
Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol (2003) 1.13
A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica (2006) 1.13
Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation (2013) 1.11
Epigenetic therapy for Friedreich ataxia. Ann Neurol (2014) 1.11
Retrospective study of 111 cases of congenital diaphragmatic hernia treated with early high-frequency oscillatory ventilation and presurgical stabilization. J Pediatr Surg (2007) 1.11
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood (2004) 1.09
Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol (2007) 1.07
Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: a Webthal study. Circulation (2013) 1.06
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica (2009) 1.05
Effect of drying conditions and storage period on polyphenolic content, antioxidant capacity, and ascorbic acid of prunes. J Agric Food Chem (2004) 1.01
Split-liver transplantation eliminates the need for living-donor liver transplantation in children with end-stage cholestatic liver disease. Transplantation (2003) 0.99
Key role of ethanol-derived acetaldehyde in the motivational properties induced by intragastric ethanol: a conditioned place preference study in the rat. Alcohol Clin Exp Res (2007) 0.95
Severe iron overload in Blackfan-Diamond anemia: a case-control study. Am J Hematol (2009) 0.94
Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. Malar J (2010) 0.93
Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. Biol Blood Marrow Transplant (2009) 0.91
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood (2003) 0.91
Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs. J Bone Miner Metab (2004) 0.90
Effectiveness of bibliographic searches performed by paediatric residents and interns assisted by librarians. A randomised controlled trial. Health Info Libr J (2011) 0.90
A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.89
Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. J Clin Pharmacol (2008) 0.88
Cholelithiasis in thalassemia major. Eur J Haematol (2008) 0.87
Apricot melanoidins prevent oxidative endothelial cell death by counteracting mitochondrial oxidation and membrane depolarization. PLoS One (2012) 0.86
Current status in iron chelation in hemoglobinopathies. Curr Mol Med (2008) 0.86
Homozygosity for transferrin receptor-2 Y250X mutation induces early iron overload. Haematologica (2004) 0.84
Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. J Cardiovasc Magn Reson (2011) 0.82
Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem (2013) 0.81
A child with hyperferritinemia: case report. Ital J Pediatr (2011) 0.81
A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer (2002) 0.80
Successful bleeding control by a combined conventional surgical approach and video-assisted surgery: a case report. Ann Thorac Cardiovasc Surg (2009) 0.80
The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. Curr Med Res Opin (2004) 0.80
α-globin gene quadruplication and heterozygous β-thalassemia: a not so rare cause of thalassemia intermedia. Acta Haematol (2013) 0.79
Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. Am J Med (2013) 0.79
Different approaches for noninvasive prenatal diagnosis of genetic diseases based on PNA-mediated enriched PCR. Ann N Y Acad Sci (2006) 0.79
Structure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic properties. Angew Chem Int Ed Engl (2012) 0.79
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study. Haematologica (2007) 0.79
Exploiting the nano-sized features of microfibrillated cellulose (MFC) for the development of controlled-release packaging. Colloids Surf B Biointerfaces (2013) 0.79
Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. Am J Hematol (2014) 0.79
Balloon dilatation of postoperative small bowel anastomotic stricture in an infant with apple peel intestinal atresia after serial transverse enteroplasty and jejunoileal anastomosis. J Pediatr Surg (2010) 0.78
Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055. Bioorg Med Chem Lett (2012) 0.78
Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer (2004) 0.78
Clinical management of cardiovascular complications in patients with thalassaemia major: a large observational multicenter study. Eur J Echocardiogr (2011) 0.77
In utero transplantation of human cord blood cells into rabbits. Transplantation (2005) 0.77
Prune melanoidins protect against oxidative stress and endothelial cell death. Front Biosci (Elite Ed) (2011) 0.77
Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors. Bioorg Med Chem Lett (2012) 0.76
Chronic cough and eosinophilic esophagitis: an uncommon association. Case Rep Gastroenterol (2011) 0.75
Exercise Stress Echocardiography with Tissue Doppler Imaging (TDI) Detects Early Systolic Dysfunction in Beta-Thalassemia Major Patients without Cardiac Iron Overload. Mediterr J Hematol Infect Dis (2012) 0.75
Management of pulmonary arterial hypertension associated to thalassemia: when pulmonary endarterectomy is the best therapeutical option? A case report. J Thromb Thrombolysis (2015) 0.75
Increased leucocyte apoptosis in transfused β-thalassaemia patients. Br J Haematol (2012) 0.75
Inspiratory stridor in a 12-month-old girl. Pediatr Int (2007) 0.75
Real life juvenile toxicity case studies: the good, the bad and the ugly. Reprod Toxicol (2008) 0.75
Lower gastrointestinal bleeding in a newborn caused by isolated intestinal vascular malformation. Pediatr Radiol (2002) 0.75
Conditioning of neonatal pigs using low-dose chemotherapy and murine fetal tissue before murine hybridoma transplantation. Transplantation (2005) 0.75
Unique method to manage ingested magnets. J Pediatr Gastroenterol Nutr (2013) 0.75
Use of cine phase-contrast MRI in the assessment of distal splenorenal shunt function. Magn Reson Imaging (2012) 0.75
Co-administration of darunavir and a new pharmacokinetic booster: formulation strategies and evaluation in dogs. Eur J Pharm Sci (2010) 0.75